HSD3B2

HSD3B2 encodes a bifunctional NAD⁺-dependent microsomal 3β-hydroxysteroid dehydrogenase/Δ5→Δ4-isomerase that catalyzes the obligatory conversion of Δ5-steroids (pregnenolone, DHEA, 17-OH pregnenolone) to their Δ4-products (progesterone, androstenedione, 17-OH progesterone), a rate-limiting step in adrenal and gonadal steroidogenesis (PMID:10599696). Catalytic competence requires an intact NAD⁺-binding domain — Ala10 is essential for all detectable activity, and the L239–Q251 loop modulates Vmax without affecting substrate affinity — while mutations near the substrate-binding pocket differentially impair conversion of individual Δ5-substrates (PMID:10843183, PMID:25322271, PMID:24372086). Transcription of HSD3B2 is positively regulated by YY1 (via intron 1 elements), GATA1 (via the proximal promoter), and Nur77 (recruited upon cAMP stimulation), while mitochondrial complex I inhibition by metformin or rotenone suppresses both expression and activity independently of AMPK (PMID:15291746, PMID:30650063, PMID:26465200, PMID:22778212). Loss-of-function mutations cause 3β-hydroxysteroid dehydrogenase deficiency, a form of congenital adrenal hyperplasia in which complete activity loss produces salt-wasting disease and partial activity loss produces a non-salt-losing phenotype (PMID:10599696).

1. 1999 High

   Systematic functional characterization of 25 disease-causing HSD3B2 missense mutations established that the degree of residual enzyme activity directly determines clinical severity (salt-wasting vs. non-salt-losing congenital adrenal hyperplasia) and identified protein instability as a novel pathogenic mechanism, transforming genotype–phenotype understanding.

   Evidence Site-directed mutagenesis with transient expression in 293 cells using [¹⁴C]-DHEA substrate conversion, Northern/Western blot, and in vitro translation

   PMID:10599696

   Open questions at the time

   • Structural basis for instability of specific mutant proteins not determined
   • Residual activity measured in heterologous cells may not reflect in vivo adrenal/gonadal context
2. 2000 High

   Demonstration that the A10E mutation in the NAD⁺-binding domain abolishes all catalytic activity established Ala10 as essential for cofactor binding and enzyme function, pinpointing the cofactor-binding domain as a critical determinant of HSD3B2 activity.

   Evidence Site-directed mutagenesis and enzyme activity assay in transfected Ad293 cells

   PMID:10843183

   Open questions at the time

   • No crystal structure or direct cofactor-binding measurement to confirm NAD⁺ interaction at Ala10
   • Other residues in the NAD⁺-binding domain not systematically tested
3. 2004 High

   Identification of YY1 as a transcription factor binding two sites in intron 1 and required for maximal basal HSD3B2 promoter activity provided the first defined cis-regulatory mechanism for HSD3B2 expression.

   Evidence Gel shift, antibody supershift, mutagenesis of YY1 sites, and reporter gene assays

   PMID:15291746

   Open questions at the time

   • Cell type-specific relevance of YY1 in adrenal vs. gonadal tissues not tested
   • Chromatin-level confirmation (e.g., ChIP) was not performed
4. 2010 High

   Co-localization of HSD3B2 and CYB5A at the zona fasciculata/reticularis border, combined with loss-of-function experiments, established that androstenedione production in the adrenal requires cooperative activity of both enzymes, explaining zonal heterogeneity in adrenal androgen output.

   Evidence Immunohistochemistry on human adrenal tissue, trilostane inhibition, and siRNA knockdown of CYB5A in H295R cells

   PMID:21185375

   Open questions at the time

   • Whether HSD3B2 and CYB5A physically interact or function independently at the same membrane is unknown
   • Mechanism establishing their co-expression in border-zone cells not identified
5. 2012 High

   Metformin and rotenone both inhibit HSD3B2 expression and activity via mitochondrial complex I inhibition (independently of AMPK), revealing an unexpected link between mitochondrial electron transport and steroidogenic gene regulation.

   Evidence Pharmacological inhibition with metformin and rotenone in NCI-H295R cells, complex I activity assay, Western blot, mRNA quantification

   PMID:22778212

   Open questions at the time

   • Signaling intermediates between complex I and HSD3B2 transcription/activity not identified
   • Relevance to in vivo adrenal steroidogenesis during metformin therapy not confirmed in human tissue
6. 2014 Medium

   Novel mutations (Y190C, S218P) near the modeled substrate-binding pocket showed substrate-selective impairment, retaining higher residual activity for 17-OH pregnenolone than other Δ5-steroids, revealing that distinct residues contribute differentially to binding of individual substrates.

   Evidence Site-directed mutagenesis, enzyme activity assay in transfected cells, 3D homology modeling

   PMID:24372086

   Open questions at the time

   • Substrate selectivity based on homology model without experimental structural validation
   • Observation from a single lab, not independently replicated
   • Kinetic parameters (Km, Vmax) for each substrate not fully determined
7. 2015 High

   Kinetic characterization of the G250V mutation showed reduced Vmax without altered Km or mislocalization, identifying the L239–Q251 loop as important for catalytic turnover rather than substrate recognition, and decanoic acid was shown to suppress HSD3B2 transcription by blocking Nur77 recruitment to the promoter, adding Nur77 to the roster of direct HSD3B2 transcriptional regulators.

   Evidence Enzyme kinetics in COS-7 cells with homology modeling (G250V); ChIP for Nur77 at HSD3B2 promoter, RT-PCR, Western blot in H295R cells with in vivo PCOS rat validation (decanoic acid)

   PMID:25322271 PMID:26465200

   Open questions at the time

   • No crystal structure to confirm loop conformation or catalytic mechanism
   • Nur77 ChIP performed only in H295R cells; relevance across steroidogenic tissues unknown
8. 2016 Medium

   Ruling out DNA methylation as the mechanism for zona reticularis-specific HSD3B2 down-regulation narrowed the search for the epigenetic or trans-acting factor responsible for adrenal zonal expression patterning.

   Evidence Bisulfite sequencing and methylation analysis on microdissected human adrenal zones

   PMID:27670690

   Open questions at the time

   • Alternative epigenetic marks (histone modifications, chromatin accessibility) not examined
   • Single-lab study on limited number of adrenal specimens
   • The actual mechanism of zone-specific silencing remains unidentified
9. 2019 High

   Identification of GATA1 as a direct transcriptional activator of HSD3B2 — binding the proximal promoter and being required for basal expression — completed a picture of three distinct positive regulators (YY1, Nur77, GATA1) acting at different promoter/intronic elements.

   Evidence Dual luciferase reporter assay, GATA1 RNAi, HSD3B2 promoter site-directed mutagenesis, in vivo PCOS rat model

   PMID:30650063

   Open questions at the time

   • Combinatorial or hierarchical relationships among YY1, Nur77, and GATA1 at the HSD3B2 locus not established
   • GATA1 role validated primarily in H295R cells; relevance to gonadal HSD3B2 expression unknown

• An experimentally determined three-dimensional structure for HSD3B2 is lacking, and the mechanism by which mitochondrial complex I status is transduced to HSD3B2 transcriptional regulation remains unknown; additionally, the cis-regulatory logic governing adrenal zone-specific silencing has not been identified.
• No crystal or cryo-EM structure available
• Signaling pathway from complex I to HSD3B2 transcription undefined
• Mechanism of zona reticularis-specific HSD3B2 silencing unresolved
• Combinatorial regulation by YY1, Nur77, and GATA1 not integrated